Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$66.42
+1.5%
$62.88
$52.50
$77.00
$1.44B0.57320,328 shs118,257 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$14.97
+1.7%
$16.34
$9.57
$29.86
$2.07B0.931.61 million shs2.10 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$45.63
+1.1%
$40.99
$19.45
$53.27
$2.97B2.18617,947 shs315,023 shs
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
$1.25
$0.35
$1.78
$344.32M0.51172,401 shs63,510 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-1.34%+0.34%-0.23%-5.13%+5.18%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-12.23%-20.96%-3.98%+19.01%-48.02%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-2.25%+0.53%-1.59%+56.74%+4.73%
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.00%0.00%0.00%0.00%+671.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.88 of 5 stars
2.51.00.03.33.23.31.3
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.9062 of 5 stars
3.42.00.03.43.91.70.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.1806 of 5 stars
4.51.00.00.03.32.50.0
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8818.75% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71192.11% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.05
Buy$59.1129.55% Upside
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest YSB, ANIP, ARWR, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$84.00
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $60.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.34$7.61 per share8.73$19.11 per share3.48
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M582.16N/AN/A$1.54 per share9.72
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M63.12N/AN/A$12.90 per share3.54
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
$560.76M0.00N/AN/A$1.14 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.78N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/A19.71N/A-45.33%-12.49%8/6/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
-$21.17MN/A0.00N/AN/AN/AN/AN/AN/A

Latest YSB, ANIP, ARWR, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q3 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.94N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.31
5.15
5.15
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
0.26
0.94
0.73

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
52.64%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
12.70%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
4.30%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million18.91 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million132.16 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
YS Biopharma Co., Ltd. stock logo
YSB
YS Biopharma
77393.06 millionN/ANot Optionable

Recent News About These Companies

YS Life
LakeShore changes CEO with new executive appointments
LakeShore Biopharma Co Ltd Ordinary Shares LSB
LSB LakeShore Biopharma Co., Ltd
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$66.42 +1.01 (+1.54%)
Closing price 03:58 PM Eastern
Extended Trading
$66.33 -0.09 (-0.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$14.96 +0.26 (+1.73%)
Closing price 03:58 PM Eastern
Extended Trading
$14.94 -0.03 (-0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$45.63 +0.49 (+1.08%)
Closing price 03:58 PM Eastern
Extended Trading
$45.71 +0.08 (+0.18%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

YS Biopharma stock logo

YS Biopharma NASDAQ:YSB

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.